Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

6.3K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.3K
Mismatch Repair01:36

Mismatch Repair

43.5K
Overview
43.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials.

Mycoses·2026
Same author

Impact of Body Mass Index on Perioperative Outcomes in Robotic-Assisted Total Hysterectomy: A Retrospective Cohort Study.

Journal of clinical medicine·2026
Same author

Esomeprazole treatment targeting sFLT-1 signaling in preeclampsia improves placental and fetal outcome in mice.

Placenta·2026
Same author

Disseminated Tumor Cells (DTCs) in Patients with Cervical Cancer Reveal Mesenchymal Properties and Potential Therapeutic Targets-A New Perspective?

International journal of molecular sciences·2026
Same author

Clinical impact of potential drug-drug interactions between midostaurin and posaconazole in FLT3-mutated AML.

Antimicrobial agents and chemotherapy·2026
Same author

Rising Antifungal Resistance in Candidozyma auris: Signals, Gaps, and the Path Forward.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Related Experiment Video

Updated: Jan 13, 2026

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
05:16

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Published on: August 4, 2021

3.7K

Microsatellite Instability Status and Mismatch Repair Defects Testing in Endometrial Cancer-Insights from the

Büsra Eser1, David Papior1, Jon Salmanton-García2,3,4,5

  • 1Department of Gynecology and Obstetrics, Medical Faculty, University Hospital of Essen, University of Duisburg-Essen, 45147 Essen, Germany.

Diagnostics (Basel, Switzerland)
|January 10, 2026
PubMed
Summary

Mismatch repair (MMR) and microsatellite instability (MSI) testing rates significantly increased in German endometrial cancer care from 2018-2022. This reflects successful guideline implementation, though guideline updates may be needed for timely adoption.

Keywords:
endometrial cancerimmune checkpoint inhibitionmicrosatellite instabilitymismatch repair-testingmolecular characterization

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.7K

Related Experiment Videos

Last Updated: Jan 13, 2026

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage
05:16

Multiplexed Fluorescent Immunohistochemical Staining of Four Endometrial Immune Cell Types in Recurrent Miscarriage

Published on: August 4, 2021

3.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
28:15

Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer

Published on: July 28, 2010

12.7K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Clinical Pathology

Background:

  • Mismatch repair (MMR) and microsatellite instability (MSI) testing are crucial for endometrial cancer (EC) molecular classification.
  • These biomarkers guide adjuvant treatment and eligibility for immune checkpoint inhibitors.
  • International guidelines recommend universal testing, but real-world implementation is inconsistent.

Purpose of the Study:

  • To evaluate trends in MMR and MSI testing rates in German endometrial cancer patients between 2018 and 2022.
  • To analyze the adoption of associated molecular diagnostics, including POLE, TP53, and L1CAM testing.
  • To assess the translation of molecular testing guidelines into clinical practice.

Main Methods:

  • Retrospective multicenter analysis of histologically confirmed EC cases in German tertiary care centers (2018-2022).
  • Data extracted from electronic pathology records, analyzing annual testing rates for MSI, MMR, POLE, TP53, and L1CAM.
  • Statistical trend analysis (Chi-square test for trend) and collection of therapeutic data on immune checkpoint inhibitor use.

Main Results:

  • Significant increases observed in annual testing rates for MSI, POLE, TP53, and L1CAM from 2018 to 2022 (p < 0.05).
  • TP53 testing surged from 13.1% to 78.6%, and MSI testing rose from 82.9% to 97.4%.
  • POLE and L1CAM testing increased from minimal levels (0% and 1.6%) to 15.7% by 2022.

Conclusions:

  • Demonstrates rapid and substantial implementation of MMR and MSI testing in German clinical practice.
  • Highlights successful translation of research findings into routine endometrial cancer care.
  • Suggests a time lag in guideline implementation, necessitating annual guideline updates for timely adoption.